Loading
A phase 1/2 trial of Cemiplimab in metastatic cancer and melanoma, run by OncoResponse, Inc., now recruiting.
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents is a phase 1/2 interventional study registered as NCT06090266 by OncoResponse, Inc., with 168 participants planned, started 2023-10-24 and due to reach its primary completion in 2026-08-01. Interventions recorded: OR502, Cemiplimab. Conditions listed: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Cemiplimab, Melanoma.
Shares Cemiplimab, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/